Day 2 Program

Poster Spotlight 1: Spatial and Immune Drivers of Therapeutic Response in Breast Cancer 

Day 2: December 9, 2026

7:00 AM–8:30 AM CST

Hemisfair 3

Session Details

Moderator

Ratna K. Vadlamudi, UT Health San Antonio, SAN ANTONIO, TX

PS1-1

Radiotherapy Initiates an In Situ Vaccination Program Through Sentinel Lymph Node Immune Priming Resulting in Tumor-SLN TCR Clonal Coupling in Early Breast Cancer

Julia Tchou, University of Pennsylvania, Philadelphia, PA

PS1-2

Phase Ib Randomized Trialof aMUC1 Peptide Vaccine as an Immune Interception Strategy in Ductal Carcinoma In Situ: Interim Immune Correlative Studies

Emilia J Diego, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA

PS1-3

Integrated proteomic and spatial transcriptomic profiling reveals biomarkers of response to neoadjuvant chemo-immunotherapy in patients with early-stage triple-negative breast cancer

Ioannis Zerdes, Karolinska Comprehensive Cancer Center and University Hospital & Karolinska institute, Stockholm, Sweden

PS1-4

Gene Expression Signatures in Triple‑Negative Breast Cancer (TNBC) Patients with Early Recurrence Metastases: An Exploratory Cohort Analysis

Sibylle Loibl, GBG Forschungs GmbH; Goethe University and University Medical Center Frankfurt/Main, Neu-Isenburg and Frankfurt/Main, Germany

PS1-5

Spatial multiomic analyses of clinical responders with advanced triple negative breast cancer to intratumoral IL-12 therapy.

Ryan Humphrey, Duke University, Durham, NC

PS1-6

Immune Priming and Response Biomarkers in Breast Cancer

Sangeetha Meda Reddy, University of Texas Southwestern Medical Center, Dallas, TX

PS1-7

Spatially coordinated extrafollicular DN2/3 B cell niches mark response to neoadjuvant therapy in early triple-negative breast cancer

Sheeba Irshad, King's College London, London, United Kingdom

PS1-8

A CD73+ Neutrophil-Macrophage Spatial Niche Drives Immunotherapy Resistance in Immune-Inflamed Triple-Negative Breast Cancer

Yanhui Wang, Fudan University Shanghai Cancer Center, Shanghai, China

PS1-9

Multimodal profiling reveals distinct ancestry- and environment-associated immune surveillance programmes in breast cancer

Sheeba Irshad, King's College London, London, United Kingdom

PS1-10

Greater distant recurrence-free survival in patients with immune-negative vs. immune-positive TNBC with residual disease after neoadjuvant immunotherapy (IO): a paradox across seven IO arms of the I-SPY2 Trial

Tam Binh Vinh Bui, University of California San Francisco, San Francisco, CA

PS1-11

Psychosocial stressors and cytokine profiles in Black breast cancer survivors

Ji Park, Roswell Park Comprehensive Cancer Center, Buffalo, NY

PS1-12

Spatial Drivers of Response and Resistance in Breast Cancer

Geeta Upadhyay, Uniformed Services University of Health Sciences, Bethesda, MD